Biotechnology

Vincerx Pharma

Vincerx Pharma Announces Termination of Non-Binding LOI with QumulusAI

Vincerx Pharma Terminates LOI with QumulusAI

Vincerx Pharma Cancels LOI for Potential Merger with QumulusAI

Vincerx Pharma released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.3966 (forecast USD -2.4)

Vincerx Pharma Terminates Proposed Merger with Global Digital Holdings

Vincerx Pharma Terminates Merger LOI with QumulusAI

Vincerx Pharma Canceled Non-Binding LOI With QumulusAI

Vincerx Pharma Ends Non-Binding LOI Discussion With QumulusAI

Vincerx Pharma Terminates LOI for Potential Merger with QumulusAI

Vincerx Pharma Cancels Merger LOI with QumulusAI

Vincerx Pharma Terminates Potential Merger LOI with QumulusAI

Vincerx Pharma Terminates Potential Merger with QumulusAI

Vincerx Pharma, Inc. Terminates Potential Merger with QumulusAI

Vincerx Pharma Terminates Potential Merger LOI with Global Digital Holdings

Vincerx Pharma Cancels Merger Letter of Intent with Global Digital Holdings

Vincerx Pharma Announces Termination of LOI and Initiates Liquidation

Vincerx Pharma released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -3.5694 USD (forecast -3.4 USD)

Vincerx Pharma released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -15.8451 USD (forecast -15.6 USD)

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Dynavax Tech

Multi Ways

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap